BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 29368256)

  • 1. Immunopathogenesis and immunotherapy of multiple myeloma.
    Tamura H
    Int J Hematol; 2018 Mar; 107(3):278-285. PubMed ID: 29368256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic approaches to treat multiple myeloma.
    Roeven MW; Hobo W; Schaap N; Dolstra H
    Hum Vaccin Immunother; 2014; 10(4):896-910. PubMed ID: 24335570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Multiple Myeloma.
    Tamura H; Ishibashi M; Sunakawa M; Inokuchi K
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31842518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
    Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
    Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-mediated and cellular immunotherapy in multiple myeloma.
    Ritchie DS; Quach H; Fielding K; Neeson P
    Immunotherapy; 2010 Mar; 2(2):243-55. PubMed ID: 20635931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma].
    Tamura H
    Rinsho Ketsueki; 2018; 59(10):2169-2177. PubMed ID: 30305523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
    Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
    Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune therapy in multiple myeloma.
    Luptakova K; Avigan D
    Clin Adv Hematol Oncol; 2015 Nov; 13(11):767-75. PubMed ID: 27058703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
    Neri P; Bahlis NJ; Lonial S
    Clin Cancer Res; 2016 Dec; 22(24):5959-5965. PubMed ID: 27797968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
    De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
    Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenges of checkpoint inhibition in the treatment of multiple myeloma.
    Paul B; Kang S; Zheng Z; Kang Y
    Cell Immunol; 2018 Dec; 334():87-98. PubMed ID: 30342750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
    Hoyos V; Borrello I
    Blood; 2016 Sep; 128(13):1679-87. PubMed ID: 27506540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.
    Festuccia M; Martino M; Ferrando F; Messina G; Moscato T; Fedele R; Boccadoro M; Giaccone L; Bruno B
    Expert Opin Biol Ther; 2015 Jun; 15(6):857-72. PubMed ID: 25865214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular immunotherapy in multiple myeloma.
    Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
    Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current developments in immunotherapy in the treatment of multiple myeloma.
    Köhler M; Greil C; Hudecek M; Lonial S; Raje N; Wäsch R; Engelhardt M
    Cancer; 2018 May; 124(10):2075-2085. PubMed ID: 29409124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.
    Lee SJ; Borrello I
    Cancer Treat Res; 2016; 169():207-225. PubMed ID: 27696265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.